Stelara Denied by Insurance? How to Appeal (2026 Guide)

Stelara (ustekinumab) is an IL-12/23 inhibitor with FDA approvals for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. As biosimilars launched in 2023, Stelara denials have become more complex — plans now often require biosimilar switching while also maintaining step therapy requirements for patients new to biologics. If your insurer has denied Stelara, you have strong clinical and legal arguments available on appeal.

Why Insurers Deny Stelara

Biosimilar substitution. Multiple FDA-approved ustekinumab biosimilars (Wezlana, Selarsdi, Pyzchiva, Otulfi) launched beginning in 2023 following Stelara's patent expiration. Many plans now require biosimilar ustekinumab as the preferred option and deny brand Stelara accordingly. For patients already stable on brand Stelara, a forced switch may not be clinically appropriate.

Step therapy — TNF inhibitors required first. For biologic-naive patients, most formularies require documented failure of one or more TNF inhibitors before approving any IL-12/23 or IL-23 inhibitor. This is one of the most common denial reasons for patients newly starting Stelara.

Prior conventional therapy not documented. For psoriasis, insurers require documented failure of methotrexate, cyclosporine, or phototherapy. For Crohn's disease and ulcerative colitis, prior failure of aminosalicylates, corticosteroids, and immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) is typically required before anti-TNF therapy — and anti-TNF failure is often required before ustekinumab.

Disease severity criteria not met. Plans generally require documented moderate-to-severe disease, quantified by validated scoring tools such as PASI, BSA, IGA, CDAI, Harvey-Bradshaw Index, or Mayo Score depending on the indication.

Non-preferred IL-23 agent. Some formularies now prefer newer IL-23 inhibitors (risankizumab/Skyrizi, guselkumab/Tremfya) over ustekinumab, particularly for psoriasis indications.

How to Appeal a Stelara Denial

Step 1: Identify the Exact Denial Reason

Request a copy of your insurer's clinical criteria used in the denial. Most insurers maintain clinical policy bulletins that describe exactly what they require for biologic approvals. Understanding the specific gap between your documentation and their criteria is the foundation of your appeal.

Step 2: Document Disease Severity with Validated Measures

For psoriasis, obtain current PASI score, body surface area (BSA) percentage, and Investigator Global Assessment (IGA) score. For Crohn's disease, include the Crohn's Disease Activity Index (CDAI) or Harvey-Bradshaw Index and endoscopic findings using the Simple Endoscopic Score for Crohn's Disease (SES-CD). For ulcerative colitis, include the Mayo Score and endoscopic Mayo subscore.

Step 3: Document Prior Therapy Failures Chronologically

Create a complete prior treatment history listing each required medication with start date, end date, dose, and specific reason for discontinuation (inadequate response, intolerance, contraindication). For step therapy, this documentation must be specific enough to satisfy your insurer's "failure" criteria — many plans require a minimum treatment duration and a specific outcome measure.

Step 4: Invoke Step Therapy Override If Applicable

More than 30 states have enacted step therapy override laws requiring insurers to grant exceptions when: (1) prior required therapy was tried and failed; (2) required therapy is contraindicated or would cause harm; or (3) clinical guidelines support the requested drug. Cite your state's specific law in your appeal. The ACCEPT trial demonstrated ustekinumab 90mg superiority over etanercept (PASI 75: 73.8% vs 56.8%) — this supports clinical exception arguments for psoriasis patients.

Step 5: Request Peer-to-Peer Review

Ask your prescribing dermatologist, rheumatologist, or gastroenterologist to request a peer-to-peer review with the insurer's medical director. This direct physician-to-physician conversation resolves many denials that persist after written appeals, particularly when the prescriber can cite trial data and guidelines specific to your clinical situation.

Step 6: Reference Guideline Support and Trial Data

The UNIFI trial for Crohn's disease and ulcerative colitis showed clinical remission at week 44 maintenance of 38.5% vs. 22.5% for placebo. The AAD/NPF guidelines recommend ustekinumab as a high-evidence option for moderate-to-severe psoriasis. The ACR 2021 PsA guidelines list ustekinumab as a recommended biologic for psoriatic arthritis with inadequate DMARD response. The AGA guidelines recommend ustekinumab for moderate-to-severe Crohn's disease after anti-TNF failure.

What to Include in Your Appeal

• Two or more validated disease severity scores taken within the past 90 days confirming moderate-to-severe disease
• Complete prior treatment history with dates, doses, and documented outcomes for each required step therapy agent
• Letter from your specialist directly addressing the denial reason and explaining the clinical rationale for Stelara
• Relevant clinical trial citations (PHOENIX 1, PHOENIX 2, ACCEPT, UNIFI) and professional society guideline references
• State step therapy override law citation if your state has enacted such legislation

Fight Back With ClaimBack

Stelara denials involving biosimilar switching, step therapy, and multi-indication clinical arguments require a precisely structured appeal. ClaimBack generates Stelara-specific appeal letters that address your exact denial reason with guideline citations and trial data. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal